Can cannabis be used as an acute treatment during a migraine attack?

Some patients use vaporised cannabis acutely at the onset of an attack and report benefit. However, the evidence for acute treatment is less well established than for preventive use, and the risk of contributing to medication overuse headache with frequent acute dosing is a clinical concern.

Will medical cannabis interact with my triptans?

Clinically significant interactions between cannabis-based medicines and triptans are not well documented, but your prescribing specialist must review your full medication list. Never alter your existing acute migraine medications without medical guidance.

I have been prescribed Botox for chronic migraine. Can I also use cannabis?

Botulinum toxin A injections and cannabis-based medicines are not mutually exclusive, and some patients use them concurrently under specialist supervision. Your neurologist and cannabis prescriber should be aware of each other's involvement in your care.

Does medical cannabis help cluster headaches?

Cluster headache is a distinct primary headache disorder from migraine. Some patients report benefit, but the evidence base is even more limited than for migraine. Specialist assessment is required.

Can I drive when using medical cannabis for migraine prevention?

THC-containing products impair driving ability. UK law sets blood-concentration limits and police use roadside DrugWipe testing. This is an important practical consideration for regular preventive dosing — discuss driving with your prescribing specialist before starting treatment.

Medical Cannabis for Migraines in the UK

Migraine is one of the most disabling neurological conditions in the UK. For patients with chronic migraine — or frequent episodic migraine that has not responded to standard preventive and acute treatments — a specialist may consider cannabis-based medicines as an additional option in the management plan.

What is Migraine?

Migraine is a complex neurological disorder characterised by recurrent attacks of moderate to severe headache, typically unilateral and pulsating in quality, often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Aura — visual disturbances, sensory changes, or speech difficulties — occurs in approximately one third of migraine sufferers before or during the headache phase. Migraine attacks can last from 4 to 72 hours and can render the individual unable to function at work or in daily life.

The distinction between episodic and chronic migraine is clinically significant. Episodic migraine involves fewer than 15 headache days per month; chronic migraine is defined as 15 or more headache days per month for more than three months, of which at least eight fulfil migraine criteria. Chronic migraine is associated with higher rates of disability, depression, anxiety, and sleep disruption than episodic migraine, and it is significantly more difficult to treat. Medication overuse headache — a complicating factor in which frequent use of acute headache treatments leads to a chronic daily headache pattern — is an important consideration in patients who use acute treatments more than 10 to 15 days per month.

Standard acute treatments include triptans (sumatriptan, rizatriptan, zolmitriptan) and in some cases gepants (rimegepant) or lasmiditan. Preventive treatments — intended to reduce migraine frequency and severity — include propranolol, topiramate, amitriptyline, candesartan, and for chronic migraine with inadequate response, botulinum toxin A (Botox) injections and CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) under specialist care. Despite this extensive toolkit, a proportion of chronic migraine patients continue to experience an unacceptably high headache burden.

Medical Cannabis and Migraine — What Does the Evidence Say?

The evidence base for cannabis-based medicines in migraine is growing, though it remains less extensive than for chronic pain or neuropathic conditions. The endocannabinoid system is known to be involved in central pain processing and the trigeminovascular system — the pathway implicated in migraine pathophysiology — providing a clear biological rationale for cannabinoid intervention.

Observational studies from medical cannabis programmes report that migraine patients frequently cite headache frequency and severity reduction as primary outcomes. A retrospective study in the United States reported that medical cannabis use was associated with a significant reduction in migraine attacks per month. A small Italian randomised controlled trial found that a cannabinoid combination reduced acute migraine pain at two hours and showed preventive effects comparable to amitriptyline over three months, though with different side effect profiles.

The evidence most strongly supports the use of cannabis-based medicines in the preventive management of chronic migraine rather than as a first-line acute treatment for individual attacks. UK specialists considering prescribing for migraine will focus on whether conventional preventive strategies have been adequately tried and have failed, and whether the patient's headache burden justifies the risks and costs of cannabis-based treatment.

Who Qualifies for a Medical Cannabis Prescription for Migraine?

Confirmed diagnosis: A documented diagnosis of chronic migraine or frequent episodic migraine, ideally by a neurologist or headache specialist.
Significant headache burden: Chronic migraine (15+ headache days per month) or episodic migraine causing substantial functional impairment despite preventive treatment.
Failed conventional preventives: At least two appropriate preventive agents tried without adequate reduction in migraine frequency — for example, propranolol and topiramate, or Botox if eligible.
Absence of medication overuse: Patients using acute treatments on more than 10 to 15 days per month may need a supervised medication overuse management plan before being considered appropriate candidates for cannabis prescribing.
UK residency and adult age.

Medical Cannabis for Cluster Headaches UK

Cluster headaches are a distinct primary headache disorder — classified as a trigeminal autonomic cephalgia — characterised by attacks of extreme unilateral periorbital pain, often described as the most severe pain a person can experience. They are separate from migraine, though both conditions may rank on this page because they share the same clinical context of refractory headache disorders and cannabis-based treatment.

For patients with treatment-resistant cluster headache where licensed options — high-flow oxygen, sumatriptan, verapamil, lithium — have not provided adequate control, a specialist can prescribe cannabis-based medicines under the UK unlicensed specialist prescribing framework. A confirmed diagnosis, ideally from a neurologist, and documentation of failed conventional treatments is required.

Key points for cluster headache patients:

Cluster headache is not on the NHS approved cannabis indications list — prescribing is on a specialist clinical basis.
Most UK cannabis clinic prescribing for cluster headache uses preventive oil formulations (THC/CBD combination or CBD-dominant).
A neurologist or headache specialist involvement in diagnosis documentation is expected before a cannabis clinic will prescribe.
See our dedicated cluster headache and medical cannabis guide for full detail on the evidence and prescribing pathway.

Which UK Clinics Prescribe for Migraines and Headache Disorders?

Not all UK cannabis clinics prescribe for primary headache disorders. The clinics with the most relevant experience for migraines and cluster headaches include:

Sapphire Medical Clinics — among the most established UK cannabis clinics with neurological experience. Their team includes consultants with headache disorder expertise.
Lyphe Clinic — prescribes for chronic headache conditions and has specialist access for complex presentations. From £99.
The Medical Cannabis Clinics (TMCC) — headache disorders including migraine are accepted indications. Clinical team includes neurologists.
Mamedica — accepts chronic migraine referrals. From £95.

Contact any clinic directly before booking to confirm they accept your specific headache diagnosis and have reviewed your treatment history.

What to Expect from a Medical Cannabis Consultation for Migraine

A consultation for migraine will involve a detailed headache history: the frequency, duration, and severity of attacks, associated symptoms (aura, nausea, photophobia), triggers identified, all acute and preventive treatments tried, and current medication use. The prescribing specialist will assess for medication overuse headache, which must be addressed before or alongside any new treatment. Cannabis-based medicines for migraine are most commonly considered as a preventive therapy — taken regularly rather than only at the onset of an attack. Products used include CBD-dominant or balanced formulations, with THC-containing preparations used where pain severity and sleep disruption are significant features. Daily oil dosing is the most commonly employed approach.

How Much Does Medical Cannabis Cost for Migraine in the UK?

Initial consultation: £79 to £200.
Monthly medication: £100 to £350 per month depending on product and dose.
Follow-up appointments: £50 to £100 per session, typically every one to three months.

Medical Cannabis for Migraines UK — Dose and Product Guide

UK specialists prescribing cannabis for migraine and cluster headaches typically use one of two approaches, depending on whether the goal is acute (as-needed) relief or prophylactic (preventative) treatment:

Acute / as-needed use: THC-dominant cannabis flower for vaporisation is typically prescribed for acute migraine attacks. The rapid onset (2–10 minutes) makes it suitable for use at the start of a migraine episode. Some patients report that inhaled THC can abort a migraine if used early — before the headache phase becomes established. This is supported by observational data from the US where legal medical cannabis is more established, though UK randomised trial data are limited.

Prophylactic / daily use: Balanced THC:CBD oils are more commonly prescribed for daily preventative use. The anti-inflammatory properties of CBD and the analgesic and serotonergic activity of THC may reduce migraine frequency over time. Daily oral dosing produces stable blood levels that could theoretically prevent the cortical spreading depression believed to trigger migraines.

The typical starting protocol for migraine is low-dose CBD:THC oil in the evening, titrated upward over two to four weeks while monitoring migraine frequency in a headache diary. If flower is added for acute use, patients are instructed to use it only at migraine onset.

Cannabis for Migraines vs Triptans — How They Compare

Factor	Triptans (e.g. Sumatriptan)	Medical Cannabis (THC)
Acute relief	Strong evidence, NICE-recommended	Observational evidence; some patients report benefit
Preventative use	Not designed for daily prophylaxis	Some patients report reduced frequency with daily CBD:THC oil
Medication overuse headache risk	Yes — a known risk with frequent triptan use (>10 days/month)	Lower — cannabis does not typically cause medication overuse headache
NHS availability	Yes — widely prescribed on NHS	No — private prescription only for most patients
Typical monthly cost	Low (NHS-funded or low co-pay)	£100 – £350/month (private)

Medical cannabis is most commonly sought by migraine patients who have tried two or more conventional preventatives (e.g. beta-blockers, amitriptyline, topiramate) without adequate benefit — which is also the eligibility threshold used by most UK cannabis clinics. For patients with medication overuse headache from frequent triptan use, cannabis may also be considered as an alternative acute treatment that carries no overuse risk.

Clinical Evidence for Cannabis and Migraine

The evidence base for cannabis in migraine is growing but not yet definitive by the standards of randomised controlled trials (RCTs). Key evidence points:

Retroactive study (Migraine 2017): Cannabis reduced self-reported migraine frequency from 10.4 to 4.6 migraines per month in a study of 121 adults — a 56% reduction. The majority also reported cannabis was helpful for acute attack management.
Colorado data (2019): A prospective study showed cannabis reduced migraine frequency by nearly 50% compared with controls. Inhaled cannabis outperformed edibles for acute relief.
UK Medical Cannabis Registry (ongoing): Real-world UK outcomes data are being collected by Sapphire Medical Foundations through the registry. Interim reports have shown patient-reported improvements in pain, sleep, and anxiety — conditions closely linked to migraine burden.
Cluster headache: Some of the most compelling anecdotal evidence for cannabis in headache disorders is in cluster headaches (sometimes called "suicide headaches"), where conventional treatments (sumatriptan injections, high-flow oxygen) are not always sufficient. The serotonergic activity of THC and the potential role of the endocannabinoid system in pain modulation are the proposed mechanisms.

NICE guidelines do not currently endorse cannabis for migraine. UK specialists prescribe on an individual clinical basis when conventional treatments have been inadequate.

Frequently Asked Questions — Medical Cannabis for Migraines UK

Can cannabis be used as an acute treatment during a migraine attack?: Some patients use vaporised cannabis acutely at the onset of an attack, and some report benefit. However, the evidence for acute migraine treatment is less well established than for preventive use, and the risk of contributing to medication overuse headache with frequent acute dosing is a clinical concern.
Will medical cannabis interact with my triptans?: Clinically significant interactions between cannabis-based medicines and triptans are not well documented, but your prescribing specialist must review your full medication list before prescribing. Never alter your existing acute migraine medications without medical guidance.
I have been prescribed Botox for chronic migraine. Can I also use cannabis?: Botulinum toxin A injections and cannabis-based medicines are not mutually exclusive, and some patients use them concurrently under specialist supervision. Your neurologist and cannabis prescriber should be aware of each other's involvement in your care.
Does medical cannabis help cluster headaches?: Cluster headache is a distinct primary headache disorder from migraine. Some patients with cluster headache report benefit from cannabis-based medicines, but the evidence base is even more limited than for migraine. Specialist assessment is required and cluster headache patients should be under care of a headache specialist.
Can I drive when using medical cannabis for migraine prevention?: THC-containing products impair driving ability. UK law sets blood-concentration limits and police use roadside DrugWipe testing. This is an important practical consideration for regular preventive dosing. Discuss driving fully with your prescribing specialist before starting treatment.